前FDA局长Scott Gottlieb表示,美国财政部保护国家安全的出发点正确,但需警惕过宽限制损害公共卫生目标,影响患者获取全球创新。他指出新政策可能限制几乎任何对中国生物技术运营的投资,包括设立实验室或合资,从而阻碍将中国创新带给美国患者。他呼吁同等重视提升美国自身流程效率与竞争力,尤其是Phase 1试验和IND阶段。
Treasury is right to try to protect national security. But we should watch for broad restrictions that could undermine our public health goals - impacting patient access to global innovation.
The new policy could curtail virtually any investment in Chinese biotech operations, including establishing labs, or entering into joint ventures, thwarting opportunities to bring Chinese innovation to American patients.
We need to focus equal attention on making our own process more efficient and competitive, especially Phase 1 trials and the IND stage. The discussion on this will be important. We must get this balance right and ensure Americans continue to benefit from the best global science.
IMO… it is a mistake to “try to increase U.S. competitiveness through protectionism.” The new rule “may make it easier for non-U.S. companies to succeed through manufacturing in China. This wouldn’t help our global competitiveness.” IMO… let’s instead kick ass with American ingenuity! https://www.biocentury.com/article/661295/draft-u-s-outbound-investment-rule-could-chill-cross-border-collaboration在 X 查看被引用的帖子
来源:Scott Gottlieb, MD 🇺🇸 · x.com